User login
Key clinical point: Some patients with atopic dermatitis (AD) who failed to achieve ≥75% improvement in Eczema Area and Severity Index (EASI)-75 and Investigator’s Global Assessment score of 0/1 (IGA 0/1) after initial 16-week treatment with dupilumab seemed to benefit from continued long-term treatment.
Major finding: Among patients with a suboptimal 16-week response to dupilumab, 91% achieved EASI-75 by week 100 with 49% of patients receiving initial dupilumab once weekly and 45% on every 2 weeks achieving IGA 0/1 at week 100.
Study details: Findings are a post hoc analysis of 100-week data from dupilumab open-label extension study including 391 adults with moderate-to-severe AD who received 300 mg dupilumab weekly after showing suboptimal response with weekly or every 2 weeks dosing in the parent study.
Disclosures: This study was funded by Sanofi and Regeneron Pharmaceuticals, Inc. Some of the authors declared serving as a consultants, speakers, and investigators or receiving funding and honoraria from various sources. Some of the authors declared being present/former employees or shareholders of Regeneron Pharmaceuticals or Sanofi Genzyme.
Source: Armstrong A et al. Dermatol Ther (Heidelb). 2021 (Dec 13). Doi: 10.1007/s13555-021-00643-4.
Key clinical point: Some patients with atopic dermatitis (AD) who failed to achieve ≥75% improvement in Eczema Area and Severity Index (EASI)-75 and Investigator’s Global Assessment score of 0/1 (IGA 0/1) after initial 16-week treatment with dupilumab seemed to benefit from continued long-term treatment.
Major finding: Among patients with a suboptimal 16-week response to dupilumab, 91% achieved EASI-75 by week 100 with 49% of patients receiving initial dupilumab once weekly and 45% on every 2 weeks achieving IGA 0/1 at week 100.
Study details: Findings are a post hoc analysis of 100-week data from dupilumab open-label extension study including 391 adults with moderate-to-severe AD who received 300 mg dupilumab weekly after showing suboptimal response with weekly or every 2 weeks dosing in the parent study.
Disclosures: This study was funded by Sanofi and Regeneron Pharmaceuticals, Inc. Some of the authors declared serving as a consultants, speakers, and investigators or receiving funding and honoraria from various sources. Some of the authors declared being present/former employees or shareholders of Regeneron Pharmaceuticals or Sanofi Genzyme.
Source: Armstrong A et al. Dermatol Ther (Heidelb). 2021 (Dec 13). Doi: 10.1007/s13555-021-00643-4.
Key clinical point: Some patients with atopic dermatitis (AD) who failed to achieve ≥75% improvement in Eczema Area and Severity Index (EASI)-75 and Investigator’s Global Assessment score of 0/1 (IGA 0/1) after initial 16-week treatment with dupilumab seemed to benefit from continued long-term treatment.
Major finding: Among patients with a suboptimal 16-week response to dupilumab, 91% achieved EASI-75 by week 100 with 49% of patients receiving initial dupilumab once weekly and 45% on every 2 weeks achieving IGA 0/1 at week 100.
Study details: Findings are a post hoc analysis of 100-week data from dupilumab open-label extension study including 391 adults with moderate-to-severe AD who received 300 mg dupilumab weekly after showing suboptimal response with weekly or every 2 weeks dosing in the parent study.
Disclosures: This study was funded by Sanofi and Regeneron Pharmaceuticals, Inc. Some of the authors declared serving as a consultants, speakers, and investigators or receiving funding and honoraria from various sources. Some of the authors declared being present/former employees or shareholders of Regeneron Pharmaceuticals or Sanofi Genzyme.
Source: Armstrong A et al. Dermatol Ther (Heidelb). 2021 (Dec 13). Doi: 10.1007/s13555-021-00643-4.